India, July 23 -- Johnson & Johnson (JNJ) on Thursday reported positive results from the Phase 3 MonumenTAL-6 trial, with both the Tecvayli plus Talvey and Talvey with pomalidomide treatment arms exhibiting significant improvements in progression-free survival and overall survival in patients with relapsed or refractory multiple myeloma who had previously received an anti-CD38 antibody and lenalidomide.
Talvey is a bispecific T-cell engaging antibody that targets the CD3 receptor expressed on the T-cell and G protein-coupled receptor class C group 5 member D (GPRC5D) surface.
Talvey, as monotherapy, was granted accelerated approval by the FDA in 2023 for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM)...